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Bm-CPI-2, a cystatin homolog secreted by the filarial parasite
Brugia malayi, inhibits class II MHC-restricted
antigen processing
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While interference with the class I MHC pathway by Results and discussion
Two B. malayi cystatin-like genes that are homologous topathogen-encoded gene products, especially those
of viruses, has been well documented, few examples type 2 cystatins were recently identified. Their sequence,
homology to mammalian cystatins, and developmentalof specific interference with the MHC class II
pathway have been reported. Potential targets for expression pattern will be fully described elsewhere
(W. F. Gregory et al., submitted). Bm-CPI-1 and Bm-CPI-2such interference are the proteases that remove
the invariant chain chaperone and generate (hereafter referred to as CPI-1 and CPI-2) both have the
conserved Q-x-V-x-G and PW motifs that are found in allantigenic peptides. Indeed, recent studies indicate
that immature dendritic cells express cystatin C to type 2 cystatins and are known to form part of the inhibi-
tory site that is directed at the papain-like, or C1, familymodulate cysteine protease activity and the
expression of class II MHC molecules [1]. Here, we of cysteine proteases [2]. Interestingly, CPI-2 also has a
conserved SND motif that was recently shown to consti-show that Bm-CPI-2, a recently discovered cystatin
homolog produced by the filarial nematode parasite tute a distinct second inhibitory site that is specific for
the C13 family of cysteine proteases, which includesBrugia malayi (W. F. Gregory et al., submitted),
inhibits multiple cysteine protease activities found asparaginyl endopeptidase (AEP), or legumain [3]. In ad-
dition, Bm-CPI-2 is expressed and secreted during para-in the endosomes/lysosomes of human B
lymphocyte lines. CPI-2 blocked the hydrolysis of sitic stages that mature in the mammalian host and, there-
fore, has the potential to interfere with host cysteinesynthetic substrates favored by two different
families of lysosomal cysteine proteases and protease activities. We therefore decided to focus on the
CPI-2 protein.blocked the in vitro processing of the tetanus toxin
antigen by purified lysosome fractions. Moreover,
CPI-2 substantially inhibited the presentation of We first tested the capacity of CPI-2 to block protease
selected T cell epitopes from tetanus toxin by living activities present in the endosomes and lysosomes of hu-
antigen-presenting cells. Our studies provide the man antigen-presenting cells (APC). A preliminary analy-
first example of a product from a eukaryotic parasite sis showed that recombinant CPI-2 inhibited the cysteine
that can directly interfere with antigen protease papain (W. F. Gregory et al.), raising the possibil-
presentation, which, in turn, may suggest how filarial ity that lysosomal cysteine proteases might be targets of
parasites might inactivate the host immune these parasite gene products.
response to a helminth invader.
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Current Biology 2001, 11:447–451 We next tested the capacity of CPI-2 to block antigen
processing in vitro. Recent studies demonstrate that the
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gen requires the activity of AEP to initiate processing [5,
6]. To test the effect of CPI-2 on TT processing, we set
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Figure 1
B. malayi CPI-2 inhibits multiple lysosomal
cysteine proteases. The protease substrates
(40 mM) shown, favored by cathepsin B/L
(stippled bars), cathepsin S (gray hatched
bars), and AEP (black bars), were incubated
with 1 mg lysosomal protein in the presence
of increasing concentrations of recombinant
CPI-2 or human cystatin C (Calbiochem),
essentially as described [5]. The buffer
contained 50 mM citrate (pH 5.5), 1 mM
EDTA, 5 mM DTT, and 0.1% CHAPS (AEP)
or Brij 35 (Cathepsin S, B, and L). Release
of 7-amido-4-methyl coumarin (NHmec) was
measured after 30 min at 460 nm on a
Cytofluor 4000 Fluorimeter (Perseptive
Biosystems). CPI-2 was expressed as a
hexa-histidine-tagged product in the pET-29T
vector (Novagen) as described (W. F.
Gregory et al., submitted, [4]). Enriched
lysosomal fractions were prepared from EBV-
transformed B cell lines as described [5]. More
than five experiments were performed, and
the result of one experiment is shown and
expressed as the mean of duplicate points.
up TT digestions in vitro using either purified B cell shown in Figure 2c, a similar pattern emerged in that
presentation to some clones, for example, AL 81 and ALlysosomes or purified pig kidney AEP as a source of prote-
ases. As shown in Figure 2a, the inclusion of increasing 127, were dramatically inhibited in the presence of CPI-2,
while presentation to others, for example, AL 15, wasamounts of CPI-2 clearly inhibited the processing of the
TTCF antigen. Similar results were obtained when lyso- barely affected. (Note that in this series of experiments,
the CPI-2 inhibitor was only tested at the 4 hr time point).somal extracts were used instead of purified AEP. Thus,
CPI-2 is able to block cysteine protease action on both Thus, CPI-2 induced a dramatic, but selective, effect on
the presentation of T cell epitopes in the tetanus toxinartificial substrates and on authentic protein substrates.
antigen. The presentation of four different epitopes rec-
ognized by T cells from two different donors was inhib-These results raised the possibility that CPI-2 might be
ited, whereas the presentation of epitope 950–961 toable to interfere with TTCF processing in living cells.
clones from both donors remained intact. This strikingTo test this, we examined the kinetics of tetanus toxin
result rules out the possibility that CPI-2 exerts somepresentation, in the presence and absence of the CPI-2
nonspecific effect on APC or T cell function.protein, to specific T cell clones generated from two dif-
ferent donors. EBV-transformed B cell lines established
from each donor were pulsed with TTCF antigen and CPI-2 appears to inhibit a broad range of lysosomal cyste-
ine proteases in lysosomal extracts from APC that arefixed at different times prior to coculture with autologous
T cell clones. To test the effect of CPI-2, the antigen required for both antigen and invariant chain (Ii) pro-
cessing. We directly tested the possibility that CPI-2presenting EBV-transformed B cells were preincubated
with 200 mg/ml CPI-2 prior to antigen pulsing. Relatively could affect Ii processing by including CPI-2 in both
in vitro digestions of biosynthetically labeled class II/Iihigh concentrations of the parasite cystatin were used
because uptake of proteins by fluid phase pinocytosis in complexes and during biosynthetic pulse/chase labeling
experiments. We also tested leupeptin and cystatin C asB cells is inefficient relative to other APC types. As shown
in Figure 2b, the presentation to T cell clone AK 48 controls. As shown in Figure 3a, the p31 isoform of Ii was
efficiently digested by crude lysosomal extracts, and this(specific for TT residues 950–961) was essentially unaf-
fected by the presence of CPI-2. However, the presenta- could be significantly, though not completely, inhibited
by the presence of leupeptin, cystatin C, or recombinanttion to clones AK 111 and AK 50 (both specific for 1235–
1246) was clearly slower in the presence of CPI-2, while CPI-2. Because Iip31 was difficult to resolve from the
class II MHC a chain, we quantitated the relative amountpresentation to clones AK 5 and AK 90 (specific for 1145–
1156) was barely detectable even after 4 hr of antigen of the Iip22 processing intermediate. In the presence of
leupeptin, cystatin C, or CPI-2, we observed a 2.3-, 2.6-,pulsing (Figure 2b). To verify these results, we also tested
a smaller panel of T cell clones from a second donor. As or 4.6-fold increase in Iip22 (Figure 3a), demonstrating
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Figure 2
(a) CPI-2 inhibits the processing and
presentation of the tetanus toxin antigen. A
histidine-tagged domain of the tetanus toxin
antigen (Mr 47 kDa) was prepared as
described [22] and incubated for 1 hr with 5
mg/ml of purified pig kidney legumain/AEP
[23] in the absence or presence of different
concentrations of CPI-2 as indicated, using
the same buffer as in the legend of Figure 1.
Samples were electrophoresed on 15%
Tris-Tricine gels and stained with Coomassie
blue. (b) CPI-2 inhibits the presentation of
multiple T cell epitopes by human B cell lines.
EBV-transformed B cell lines from donor AK
were used as antigen-presenting cells (APC)
and incubated with 50 mg/ml TTCF in the
presence (stippled bars) or absence (black
bars) of 200 mg/ml CPI-2 for various times
at 378C. The cells were then harvested,
washed, and fixed for 45 s in 0.05%
glutaraldehyde prior to coculture with T cell
clones as described [5]. After 48 hr, T cell
proliferation was measured after pulsing with
1 mCi [3H]thymidine (Amersham) and
harvested 18 hr later onto nitrocellulose filters
for scintillation counting. This experiment is
representative of five other experiments that
were performed. (c) Similar to (b), but using
B and T cells from donor AL, where CPI-2 was
tested only at the 4 hr time point. More details
on the T cell clones that were used can be
found in [5] and [11]. Note that the epitopes
recognized by clones 50, 81, and 111 have
not been precisely mapped, but the epitope
for clone 81 lies between residues 905 and
937, and the epitope for clones 50 and 111
lie in the region 1225–1257.
that in vitro CPI-2 can inhibit proteases that degrade the CPI-2-sensitive and -insensitive T cell epitopes require
processing in different compartments of the class II MHCIip22 intermediate (as well as those that degrade the Iip31
substrate). In living cells, inclusion of leupeptin during system and utilize either invariant chain–associated or
recycling populations of MHC molecules (reviewed inthe pulse/chase labeling of human class II MHC mole-
cules induces the accumulation of a 22 kDa fragment [9]). Consistent with this possibility, clones from the AL
panel showed differential requirements for presentation(LIP) of the invariant chain [7, 8] (Figure 3b). As shown
in Figure 3b, CPI-2 also induced the appearance of a on newly synthesized versus recycling class II MHC [10]
and differential sensitivity to the Helicobacter pylori toxinsimilarly sized Ii fragment and, apparently, a smaller (z18
kDa) fragment. These data indicate that CPI-2 may in- Vac A [11]. Whereas presentation to clone AL 81 was
relatively slow and sensitive to cycloheximide, clone ALhibit both antigen and invariant chain processing.
220 (which, like AL15, recognizes the epitope 950–961)
was triggered rapidly and in a cycloheximide-insensitiveWhy does the presentation of some epitopes appear to
be unaffected by CPI-2 uptake? One possibility is that manner [10]. Moreover, the latter clone was insensitive
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Figure 3 ligation, or specific antigen [13]. Since CPI-2 was not
present during the coculture of antigen-pulsed APC with
T cells in our experiments, a direct effect on T cell prolif-
eration is unlikely to be the basis of the suppression we
observed.
CPI-2 is one of the most abundant transcripts made by
infective B. malayi larvae, constituting 0.6% of ESTs se-
quenced to date [14], and its production and secretion
during the mammalian stages of the parasite life cycle
point to a role in maintaining the parasite within the host
enviroment. Adult filarial worms establish themselves in
lymphatic vessels afferent to the lymph nodes in which
the specific immune response would be initiated. Thus,
CPI-2 could gain ready access to dendritic cells and other
APC populations in lymphoid tissue, leading to the im-
pairment or ablation of antiparasite immune responses.
Although direct evidence for this hypothesis is not yet
available, two observations from in vivo infections can be
recalled. First, in dogs infected in the footpad with Brugia
pahangi (a sibling species of B. malayi), the draining lymph
node cells are far less responsive to parasite antigen than
PBL (peripheral blood lymphocytes), indicating a local
suppression of immune capacity [15]; and, second, in sero-
logical studies of infected humans, a relative loss of anti-
body reactivity to proteins .30 kDa has been observed,
suggesting a diminution of antigen-processing capacity in
the presence of heavy filarial infection [16]. However, it
CPI-2 partially blocks the processing of the Ii chain in vitro and in vivo. will be important to measure CPI-2 levels in infected
(a) EBV cells (Pala, 107 cells) were pulse labeled with 0.5 mCi lymphatic tissues.35S-Translabel (Amersham, Pharmacia Biotech) for 20 min and lysed.
Ii chain/ class II complexes were immunoprecipited with antibody
VICg1 directed against the cytoplasmic tail of the Ii chain, essentially Viral pathogens, encoding no more than 200 genes, display
as described [24]. The complexes were then digested in vitro with a remarkable array of immune evasion devices [17–19],
1 mg enriched lysosomal fractions in the absence (lane 2) or presence aimed particularly at the MHC class I pathway. Filarialof different inhibitors, leupeptin (10 mg/ml, lane 3), cystatin C (100
nematodes, with a gene complement of 15,000 or moremg/ml, lane 4), and CPI-2 (100 mg/ml, lane 5). The samples were
boiled for 5 min before analysis on a 14% Tris-Tricine gel. The [20], are likely to have evolved immune evasion strategies
amount of Ii p22 was quantitated by NIH image software. (b) The no less complex but orientated toward the class II path-
same APC were incubated for 20 min in the absence (lane 1) or way, as befits their extracellular niche. Although therepresence of leupeptin (2 mM, lane 2) or CPI-2 (200 mg/ml, lane 3),
are now examples of both viral [21] and bacterial [11]pulse labeled with 0.5 mCi/ml 35S-Translabel for 20 min, and then
pathogens targeting the class II pathway, our studies pro-chased for 2 hr in the continuous presence of the inhibitors. MHC
class II molecules were immunoprecipited with the class II b vide the first example of a product from a eukaryotic
chain–specific antibody DA6 321 and analyzed on a 12% Tris-Tricine parasite that may interfere with efficient generation and
gel as described [24].
loading of class II MHC-restricted T cell epitopes, poten-
tially hampering the host immune response to a helminth
invader.
to the effects of Helicobacter pylori toxin Vac A, which
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that CPI-2 inhibits presentation on newly synthesized,
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